| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911652 | Lung Cancer | 2005 | 6 Pages |
Abstract
Paclitaxel as single agent in stages IIIB-IV BAC was well tolerated and manageable but of limited efficacy. BAC should not be excluded from trials of new forms of chemotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Giorgio V. Scagliotti, Egbert Smit, Lionel Bosquee, Mary O' Brien, Andrea Ardizzoni, Peter Zatloukal, Wilfried Eberhardt, Maartje Smid-Geirnaerdt, Hein G. de Bruin, Sonia Dussenne, Catherine Legrand, Giuseppe Giaccone,